Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Biological peptide for treating asthma and application of biological peptide

An asthma and drug technology, applied in the field of biological peptides for the treatment of asthma, can solve the problems of difficult asthma, poor stability of peptides, and effective treatment

Active Publication Date: 2021-06-08
SHANGHAI INST OF PHARMA IND +1
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Asthma is a refractory lung disease, and existing clinical drugs are difficult to effectively treat asthma
Although, with the development of biomedical technology, many peptide drugs have been developed for asthma, but these peptides have poor stability, short half-life in vivo and are difficult to treat effectively. Therefore, they are greatly limited as therapeutic drugs.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biological peptide for treating asthma and application of biological peptide
  • Biological peptide for treating asthma and application of biological peptide
  • Biological peptide for treating asthma and application of biological peptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0203] Each 7-peptide compound stability in the rat whole blood of embodiment 1

[0204] 1.1 Experimental procedure and incubation conditions

[0205] Preparation of test samples: Dissolve and dilute SP and SIPI-D00 with an appropriate amount of 50% acetonitrile water containing 0.1% formic acid to obtain a working solution with a concentration of 200 μg / mL. Table 1 below shows the usage conditions of the stability study reagents.

[0206] Table 1 Stability study reagent usage

[0207]

[0208] 1) Add fresh rat whole blood to the EP tube, shake gently to mix;

[0209] 2) EP tubes were pre-incubated in a 37°C water bath for 5 minutes;

[0210] 3) Add each compound to initiate the reaction, and continue to incubate at 37°C;

[0211] 4) At 0, 2 min, 5 min, 10 min, 30 min, and 60 min, take 50 μL from the sample tube to the stop tube, add 50 μL of ice-cold 7% perchloric acid, oscillate, and terminate the reaction;

[0212] 5) Centrifuge at 13000 r / min for 10 min, absorb 75 ...

Embodiment 2

[0218] Example 2 Plasma drug concentration at different times after a single subcutaneous injection of SP peptide or SIPI-D00 peptide in SD rats

[0219] 1. Materials

[0220] SP peptide (amino acid sequence SEQ ID NO: 1)

[0221] SIPI-D00 polypeptide (amino acid sequence SEQ ID NO: 2)

[0222] 2. Experimental animals

[0223] Male SD rats with a body weight of about 200g were reared in an air-conditioned constant temperature room at room temperature of 20-24°C, humidity of 40-70%, light for 12 hours, and free access to food and water.

[0224] 3. Experimental method

[0225] 3.1 Administration method

[0226] Route: single dorsal subcutaneous injection;

[0227] Dosage of drugs: SP peptide and SIPI-D00 peptide were prepared into 3.33 mg / mL solution with normal saline, the dosage of SP peptide subcutaneously injected on the back was 10 mg / kg body weight, and the administration of SIPI-D00 peptide subcutaneously injected on the back The dose is 5mg / kg body weight.

[022...

Embodiment 3

[0261] Example 3 Effect of SP Peptide and SIPI-D00 Peptide on ConA (Concanavalin A) Stimulation of Mouse Splenocytes to Secrete IL-4

[0262] Asthma is mainly an inflammatory disease mediated by Th2 cells. During disease progression, Th2 cells secrete IL-4, IL-5, and IL-13, and these cytokines act on eosinophils, mast cells, and airway structural cells to promote the accumulation of inflammatory cells in the bronchial mucosal epithelium and play a refactoring. Therefore, by examining the effects of SP peptide and SIPI-D00 peptide on the secretion of IL-4 to evaluate their therapeutic effect on asthma.

[0263] 1. Experimental method

[0264] Three BALB / C mice were sacrificed by cervical dislocation after anesthesia. Soak in 75% ethanol for 5 minutes. Dissect, take spleen, prepare splenic lymphocytes, after counting, add 2×10 5 One per well, different concentrations of SP peptide and SIPI-D00 peptide were set up, and different concentrations of CsA (cyclosporine A) were used...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a biological peptide for treating asthma and application of the biological peptide. The invention also relates to a preparation method and application of the polypeptide and a pharmaceutical composition containing the polypeptide. The polypeptide disclosed by the invention has the advantages of small molecular weight, low production cost, good water solubility, good stability, long half-life period, small immunogenicity, low toxic and side effects, strong tissue penetrability and the like; and moreover, the research on an OVA-induced asthma mouse model shows that the biological peptide has remarkable functions of preventing, treating and / or relieving asthma.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to a biological peptide for treating asthma and its application. Background technique [0002] Polypeptide is a kind of substance that is the same as protein in terms of amino acid composition and connection method, but is different from protein in some properties, such as its relatively simple spatial structure, low or no immunogenicity, and strong physiological activity. Wait. However, the inherent characteristics of peptides, such as low oral utilization, high enzymatic degradation, and extremely short half-life, have many limitations in their development and application as drugs. An important reason for the instability of peptide drugs is the special molecular structure of peptides. [0003] Asthma is a refractory lung disease, and the existing clinical drugs are difficult to effectively treat asthma. Although, with the development of biomedical technology, many peptide...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K7/06A61K38/08A61P11/06
CPCC07K7/06A61P11/06A61K38/00
Inventor 刘莉梅其炳马淑梅李梁刘楠顾丰华王佳慧许文琦
Owner SHANGHAI INST OF PHARMA IND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com